Education, Teaching, and Quality Improvement |

Efficacy of Levodropropizine in Pediatric and Adult Population: 2 Systematic Reviews and Meta-analysis of Published Clinical Studies FREE TO VIEW

Francesco De Blasio, MD; Luigi Lanata, MD; Giovanni Fontana, MD; Federico Saibene, MD; Alessandro Zanasi, MD
Author and Funding Information

Dompè, Milano, Italy

Chest. 2014;146(4_MeetingAbstracts):526A. doi:10.1378/chest.1991481
Text Size: A A A
Published online


SESSION TITLE: Quality & Clinical Improvement Posters I

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 29, 2014 at 01:30 PM - 02:30 PM

PURPOSE: Cough has great impact on quality of life of children and adults, thus often requiring an empiric treatment with antitussive agents. Levodropropizine is an orally-administered non-opiod agent whose peripheral antitussive action may result from its modulation of sensory neuropeptide levels within the respiratory tract. Thanks to its peripheral mechanism of action, levodropropizine is a very well tolerated drug, while central cough suppressants, such as codeine and cloperastine, may be associated with side effects, especially in children. The aim of our 2 meta-analysis is to evaluate the overall comparative efficacy of levodropropizine in both children and adults.

METHODS: A comprehensive systematic literature search was performed on main databases throughout January 2012, to identify clinical trials of levodropropizine vs. controls in adult and pediatric population. A first standardized meta-analysis of 4 controlled clinical studies of levodropropizine (3 vs central antitussives and 1 vs placebo) included a total of 780 children. A second metanalysis of 7 controlled clinical studies of levodropropizine (5 vs central drugs and 2 vs placebo) included 2633 patients, both children and adults.

RESULTS: First meta-analysis of all standardized efficacy parameters (cough frequency, severity, night awakenings) in children, showed highly statistically significant difference in the overall antitussive efficacy in favor of levodropropizine vs. controls (p = 0.001). Heterogeneity was not statistically significant (p=0.0619). Our second meta-analysis also showed statistically significant difference in the overall antitussive efficacy in favor of levodropropizine vs. control treatments (p = 0.0044). Heterogeneity was not statistically significant (p=0.0856).

CONCLUSIONS: These two standardized meta-analysis of published studies provides an overview of the major comparative evidence on levodropropizine in terms of efficacy in both children and adults.

CLINICAL IMPLICATIONS: Our results indicate that levodropropizine is an effective antitussive drug both in adults and children, with statistically significant better overall efficacy outcomes vs. central antitussives, in terms of reducing cough intensity, frequency and nocturnal awakenings and further reinforce the favorable benefit/risk profile of levodropropizine in the management of cough in pediatric and adult settings.

DISCLOSURE: Luigi Lanata: Employee: Medical affairs director Giovanni Fontana: Other: Unrestricted grant Federico Saibene: Employee: Medical Manager The following authors have nothing to disclose: Francesco De Blasio, Alessandro Zanasi

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543